Narcotic Equivalents * Pain (Adjuvants) Urinary Incontinence Approximate Equi-analgesic Doses: Special Note codeine [120 mg; 200 mg] Wound Management fentanyl Reflux (GERD) [0.1 mg; n/a] hydrocodone IN-SIGHT HOSPICE [n/a; 30 mg] DRUG FORMULARY hydromorphone & Cost Index [1.3-1.5 mg; 7.5 mg] COMMUNITY HOSPICES OF AMERICA levorphanol is pleased to provide our IN-SIGHT Pain [n/a; 4 mg] Management & Palliative Care Formulary with Cost Index. The IN-SIGHT formulary Secretions (Excessive)
*Hospice is responsible for paying for medication deemed
meperidine is designed to assist practitioners in
appropriate by the Hospice Interdisciplinary Team (IDT)
[75 mg; 300 mg] selecting appropriate and cost-effective
Community Hospices of America, Inc. drugs for their COMMUNITY HOSPICES methadone OF AMERICA patients. The drugs on this H o s p i c e A d m i s s i o n C r i t e r i a Seizures formulary have been reviewed by the [10 mg; 10-20 mg] pharmacy department and found 1 . D i a g n o s e d w i t h a t e r m i n a l appropriate for formulary inclusion. morphine Comments and suggestions from [10 mg; 30-60 mg] 2 . H a s a l i f e e x p e c t a n c y o f s i x practicing physicians have also been incorporated to ensure that the form ulary m o n t h s o r l e s s , a s oxycodone is reflective of current medical practice. d e t e r m i n e d b y t h e a t t e n d i n g [n/a; 15-30 mg] Items highlighted in GREEN are CHA p h y s i c i a n A N D t h e h o s p i c e preferred products. Items that are RED i n t e r d i s c i p l i n a r y t e a m oxymorphone are CHA’s NON-preferred. Items in Blue 3 . I s s e e k i n g p a l l i a t i v e ( p a i n & [1 mg; n/a] are alternates. s y m p t o m r e l i e f ) r a t h e r t h a n ************************ Cost Indexes are provided to assist the c u r a t i v e t re a t m e n t . pentazocine practitioners in understanding the costs of 4 . A d m i s s i o n t o h o s p i c e [30 mg; 100 mg] the medications they prescribe for hospice s e r v i c e s i s a p p r o v e d b y t h e patients. Hospice is reimbursed by a t t e n d i n g p h y s i c i a n & Medicare/Medicaid at a rate of $100+ per H o s p i c e m e d i c a l d i r e c t o r day. ALL CARE (meds, DME, nursing, 5 . T h e p a t i e n t , f a m i l y , a n d CNA, MSW, pastoral care, physician consults, therapies, bereavement, etc) a t t e n d i n g p h y s i c i a n must be achieved from that $100+ per u n d e r s t a n d t h a t a r t i f i c i a l , l i f e - day. It is imperative that CHA contain our p r o l o n g i n g p r o c e d u r e s a r e costs, but never compromise quality of n o t c o n s i s t e n t w i t h h o s p i c e care. Thank you for using this tool to assist us. 6 . T h e p a t i e n t I S N O T r e q u i r e d t o b e h o m e b o u n d . 7 . L i v e s i n t h e h o s p i c e s e r v i c e
Community Hospices of America, Inc. Anorexia-Cachexia-Wt. Loss Bowel Obstruction (Complete) Diarrhea Cost/Day Pain (Opiods) Cost/Day Constipation Dyspnea (Also consider anxiolytics)
Transdermal Fentanyl (Patch)(Duragesic)$$$$$$$$
Anxiety/Restlessness Delirium Agitation Associated w Dementia Antipsychotics Insomnia Pain (Non Opiod)
Midazolam ONLY for intentional sedation$$$$
Depression (Antidepressants) Nausea/Vomiting Asthenia (Fatigue & Weakness) Symptom/Condition Preferred Alternate NON-Preferred
Community Hospices of America, Inc.
Tramadol Hcl w APAP (Generic Ultracet)$$$$$$
Community Hospices of America, Inc.
Community Hospices of America, Inc.
Community Hospices of America, Inc.
Suri Karthikeyan, M.D. Gastroentorology & Hepatology Suri Karthikeyan, M.D., M.R.C.P., F.R.C.P. (c) INSTRUCTIONS FOR COLONOSCOPIC PREP WITH MIRALAX AND CLEAR LIQUIDS READ CAREFULLY–DO NOT EXCEED RECOMMENDED DOSAGE AS SERIOUS SIDE EFFECTS MAY OCCUR. Name: _____________________________ You have been scheduled for the above examination. Please report to: Lakeside Memori
Facing Disruption Responsive Contents and Technological Responsibility Panellists: Director, Information Systems Research Unit Director, Cynefin Centre for Organisational Complexity Abstract The panel explores an alternative conceptual framework to understand and manage the implications of non-linearly structured work forms that emerge in current work environments. The framewor